Updated time: 2022-01-21 14:47:23
28A-1100723
2021-09-13
USP
The m31A7 chimera monoclonal antibody is isolated and
cloned from mono-GlcNAc decorated spike protein
immunized mice. It has a higher affinity than all
monoclonal antibodies currently on the market. The Fab
region recognizes Spike protein of WT SARS-CoV-2 and
various variants. The m31A7 chimera monoclonal
antibody will be a powerful new drug for the treatment of
patients in the future. In addition, Cryo-EM structural
analysis showed the binding of m31A7 to RBD region in a
unique mode.
- The mono-GlcNAc decorated Spike protein immunized mice toisolate the B cells expressing the B cell receptor encodingm31A7 and recognizing Spike protein of SARS-CoV-2
- Unique binding mode with high affinity against spike protein
- SARS-CoV-2 detection/diagnosis
- SARS-CoV-2 therapy
Kuo-I Lin, Che Ma, Chi-Huey Wong, Szu-Wen Wang, Yi-Hsuan Chang, Xiaorui Chen, Han-Yi Huang
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

A m31A7 chimera monoclonal antibody possesses protective activity against various SARS-CoV-2 variants